AstraZeneca (LSE:AZN) recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, ...

Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...

AstraZeneca (AZN) says “positive” full results from the BATURA Phase IIIb trial showed the company’s anti-inflammatory reliever rescue therapy, Airsupra, demonstrated statistically significant and ...

Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has ...